UBS Group has raised its target price for Qiagen (NYSE: QGEN) from $48.00 to $50.00, maintaining a "neutral" rating on the stock. The new price objective suggests a modest potential upside of 0.02% from the current trading price. Despite this adjustment, the overall consensus among analysts remains cautious.
Other analysts have offered varying perspectives on Qiagen's stock. Barclays recently downgraded the stock from "overweight" to "equal weight" and lowered its price target from $55.00 to $53.00. In contrast, Morgan Stanley reiterated an "overweight" rating, while Stifel Nicolaus set a lower target price of $40.00. Jefferies Financial Group maintained a "buy" rating with a $48.00 target, and Citigroup restated a "neutral" rating but increased its target price to $52.00 from $45.00.
Qiagen's stock has seen mixed trading activity, closing at $49.99 on Friday, down $0.11 from the previous day. The company's market capitalization stands at $10.30 billion, with a price-to-earnings ratio of 27.32. Qiagen reported quarterly earnings of $0.65 per share, beating estimates by $0.02, and revenue of $547.87 million, slightly above expectations.
Institutional investors have been active in adjusting their positions. Amundi increased its stake by 12.4%, State Street Corp by 4.5%, and Dimensional Fund Advisors LP by 20.8%. Swiss National Bank also boosted its holdings by 21.1%, while First Trust Advisors LP initiated a new position worth $21.38 million. Currently, 70.00% of the stock is owned by institutional investors.